NCT02224014已完成不适用
Lendormin D® Tablet (Drug Use Result Survey)
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 485
- 主要终点
- Number of patients with adverse events
研究概览
简要总结
Study to investigate the safety and the efficacy in patients with insomnia, receiving Lendormin D tablet under condition of normal clinical practice.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with insomnia
排除标准
- 未提供
研究组 & 干预措施
Lendormin D tablets
干预措施: Lendormin D tablets (Drug)
结局指标
主要结局
Number of patients with adverse events
时间窗: up to 2 months
Number of patients with serious adverse events
时间窗: up to 2 months
Number of patients with adverse drug reactions
时间窗: up to 2 months
次要结局
- Physician's overall efficacy assessment on a 3-point scale(up to 2 months)
- Patient's impression questionnaire(up to 2 months)
研究者
相似试验
撤回
3 期
An Investigational Drug Study in Healthy Adult Volunteers in a Model of Insomnia (0928-007)InsomniaNCT00102154H. Lundbeck A/S
已完成
4 期
A Study to Find Out if Daridorexant is Safe and Efficacious in Patients With Insomnia and Comorbid NocturiaInsomnia DisorderNocturiaNCT05597020Idorsia Pharmaceuticals Ltd.60
终止
3 期
Adult Polysomnography Primary Insomnia Cross Over Study (0928-049)(TERMINATED)Primary InsomniaNCT00420810H. Lundbeck A/S138
招募中
4 期
Daridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer DiseaseAlzheimer DiseaseInsomnia DisorderSleepNCT05924425University Hospital, Montpellier62
终止
3 期
Elderly Primary Insomnia Polysomnographic Study (0928-002)(TERMINATED)Primary InsomniaNCT00094666H. Lundbeck A/S465